Unlikely to cause harm — often a labeling or packaging issue.
Container packaging defect.
| Brand name | CONTRAVE |
| Generic name | NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE |
| Active ingredient(s) | BUPROPION HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE |
| Distributed by / for | Orexigen therapeutics, Inc., La Jolla, CA 92037 |
| NDC | 51267-890-99 |
| Full product label | Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99 |
| Recalling firm | Orexigen Therapeutics, Inc. |
| Distribution | Within the United States |
| Quantity | 18,895 bottles |
| Recall initiated | 2018-10-05 |
| Report date | 2018-11-14 |
| Recall completed | 2019-11-15 |
| Recall number | D-0219-2019 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | La Jolla CA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗